The United Kingdom and the United States have signed a significant trade agreement that will keep zero tariffs on British pharmaceutical exports entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has committed to raise spending on medicines through the National Health Service (NHS). This move guarantees that duties on these key goods will stay at nothing for a period of 36 months.
This deal follows previous warnings to dramatically increase tariffs on patented pharmaceutical imports, with figures discussed up to one hundred percent.
"This deal with the Britain strengthens the global environment for innovative medicines and brings long-overdue equity to transatlantic pharmaceutical trade," an announcement said.
Economic Significance
Drugs constitute one of the UK's most significant exports to the US, which is clearly the primary destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months prior to last September, the UK sold drugs valued at £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This guarantee safeguards jobs, stimulates funding and paves the way for the UK to establish itself as a worldwide center for life sciences," a government official stated.
Specific NHS Changes
The agreement includes several key changes from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to raise total public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates were more than 20%.
Recent Tensions
The pact comes amid a ongoing tension between the drug companies and the ministers over medicine costs and approval rates.
These tensions were intensified by claims that US patients were charged significantly more for the same drugs than patients in the other developed nations.
Recently, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial expansions have been pledged toward projects in the United States.
The Science Minister stated that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the past decade.
